Verfügbarkeit: Race in a Bottle | Technische Universität München

Race in a Bottle: The Story of BiDil and Racialized Medicine in a Post-Genomic Age

Gespeichert in:

Bibliographische Detailangaben
Beteilige Person:	Kahn, Jonathan (VerfasserIn)
Format:	Elektronisch E-Book
Sprache:	Englisch
Veröffentlicht:	New York Columbia University Press 2012
Schlagwörter:	Geschichte 2000-2012 Rassentheorie Arzneimittelentwicklung Forschung Unternehmensinteresse Pharmakogenetik Hydralazin Medizin Rassenpolitik USA
Links:	http://www.degruyter.com/doi/book/10.7312/kahn16298 http://www.degruyter.com/doi/book/10.7312/kahn16298 http://www.degruyter.com/doi/book/10.7312/kahn16298 http://www.degruyter.com/doi/book/10.7312/kahn16298 http://www.degruyter.com/doi/book/10.7312/kahn16298 http://www.degruyter.com/doi/book/10.7312/kahn16298 http://www.degruyter.com/doi/book/10.7312/kahn16298 http://www.degruyter.com/doi/book/10.7312/kahn16298
Beschreibung:	Description based upon print version of record At a ceremony announcing the completion of the first draft of the human genome in 2000, President Bill Clinton declared, ?I believe one of the great truths to emerge from this triumphant expedition inside the human genome is that in genetic terms, all human beings, regardless of race, are more than 99.9 percent the same." Yet despite this declaration of unity, biomedical research has focused increasingly on mapping that .1 percent of difference, particularly as it relates to race.This trend is exemplified by the drug BiDil. Approved by the FDA in 2005 as the first drug with a race-specific ind
Umfang:	1 Online-Ressource (329 p)
ISBN:	9780231531276

Internformat

MARC


LEADER	00000nam a2200000zc 4500
001	BV042998643
003	DE-604
007	cr\|uuu---uuuuu
008	151111s2012 xx o\|\|\|\| 00\|\|\| eng d
020			\|a 9780231531276 \|9 978-0-231-53127-6
020			\|a 9780231531276 \|9 978-0-231-53127-6
024	7		\|a 10.7312/kahn16298 \|2 doi
035			\|a (OCoLC)818814876
035			\|a (OCoLC)818814876
035			\|a (DE-599)GBV739046837
040			\|a DE-604 \|b ger \|e aacr
041	0		\|a eng
049			\|a DE-859 \|a DE-860 \|a DE-473 \|a DE-739 \|a DE-1046 \|a DE-1043 \|a DE-858
082	0		\|a 616.042
100	1		\|a Kahn, Jonathan \|e Verfasser \|4 aut
245	1	0	\|a Race in a Bottle \|b The Story of BiDil and Racialized Medicine in a Post-Genomic Age
264		1	\|a New York \|b Columbia University Press \|c 2012
300			\|a 1 Online-Ressource (329 p)
336			\|b txt \|2 rdacontent
337			\|b c \|2 rdamedia
338			\|b cr \|2 rdacarrier
500			\|a Description based upon print version of record
500			\|a At a ceremony announcing the completion of the first draft of the human genome in 2000, President Bill Clinton declared, ?I believe one of the great truths to emerge from this triumphant expedition inside the human genome is that in genetic terms, all human beings, regardless of race, are more than 99.9 percent the same." Yet despite this declaration of unity, biomedical research has focused increasingly on mapping that .1 percent of difference, particularly as it relates to race.This trend is exemplified by the drug BiDil. Approved by the FDA in 2005 as the first drug with a race-specific ind
648		7	\|a Geschichte 2000-2012 \|2 gnd \|9 rswk-swf
650	0	7	\|a Rassentheorie \|0 (DE-588)4152838-4 \|2 gnd \|9 rswk-swf
650	0	7	\|a Arzneimittelentwicklung \|0 (DE-588)4143176-5 \|2 gnd \|9 rswk-swf
650	0	7	\|a Forschung \|0 (DE-588)4017894-8 \|2 gnd \|9 rswk-swf
650	0	7	\|a Unternehmensinteresse \|0 (DE-588)4187042-6 \|2 gnd \|9 rswk-swf
650	0	7	\|a Pharmakogenetik \|0 (DE-588)4271255-5 \|2 gnd \|9 rswk-swf
650	0	7	\|a Hydralazin \|0 (DE-588)1031904484 \|2 gnd \|9 rswk-swf
650	0	7	\|a Medizin \|0 (DE-588)4038243-6 \|2 gnd \|9 rswk-swf
650	0	7	\|a Rassenpolitik \|0 (DE-588)4115694-8 \|2 gnd \|9 rswk-swf
651		7	\|a USA \|0 (DE-588)4078704-7 \|2 gnd \|9 rswk-swf
689	0	0	\|a USA \|0 (DE-588)4078704-7 \|D g
689	0	1	\|a Hydralazin \|0 (DE-588)1031904484 \|D s
689	0	2	\|a Arzneimittelentwicklung \|0 (DE-588)4143176-5 \|D s
689	0	3	\|a Pharmakogenetik \|0 (DE-588)4271255-5 \|D s
689	0	4	\|a Rassenpolitik \|0 (DE-588)4115694-8 \|D s
689	0	5	\|a Unternehmensinteresse \|0 (DE-588)4187042-6 \|D s
689	0	6	\|a Geschichte 2000-2012 \|A z
689	0		\|8 1\p \|5 DE-604
689	1	0	\|a USA \|0 (DE-588)4078704-7 \|D g
689	1	1	\|a Medizin \|0 (DE-588)4038243-6 \|D s
689	1	2	\|a Forschung \|0 (DE-588)4017894-8 \|D s
689	1	3	\|a Rassentheorie \|0 (DE-588)4152838-4 \|D s
689	1	4	\|a Geschichte 2000-2012 \|A z
689	1		\|8 2\p \|5 DE-604
856	4	0	\|u http://www.degruyter.com/doi/book/10.7312/kahn16298 \|x Verlag \|3 Volltext
883	1		\|8 1\p \|a cgwrk \|d 20201028 \|q DE-101 \|u https://d-nb.info/provenance/plan#cgwrk
883	1		\|8 2\p \|a cgwrk \|d 20201028 \|q DE-101 \|u https://d-nb.info/provenance/plan#cgwrk
912			\|a ZDB-23-DGG
943	1		\|a oai:aleph.bib-bvb.de:BVB01-028423911
966	e		\|u http://www.degruyter.com/doi/book/10.7312/kahn16298 \|l DE-1043 \|p ZDB-23-DGG \|x Verlag \|3 Volltext
966	e		\|u http://www.degruyter.com/doi/book/10.7312/kahn16298 \|l DE-1046 \|p ZDB-23-DGG \|q FAW_PDA_DGG \|x Verlag \|3 Volltext
966	e		\|u http://www.degruyter.com/doi/book/10.7312/kahn16298 \|l DE-858 \|p ZDB-23-DGG \|q FCO_PDA_DGG \|x Verlag \|3 Volltext
966	e		\|u http://www.degruyter.com/doi/book/10.7312/kahn16298 \|l DE-859 \|p ZDB-23-DGG \|q FKE_PDA_DGG \|x Verlag \|3 Volltext
966	e		\|u http://www.degruyter.com/doi/book/10.7312/kahn16298 \|l DE-860 \|p ZDB-23-DGG \|q FLA_PDA_DGG \|x Verlag \|3 Volltext
966	e		\|u http://www.degruyter.com/doi/book/10.7312/kahn16298 \|l DE-473 \|p ZDB-23-DGG \|q UBG_PDA_DGG \|x Verlag \|3 Volltext
966	e		\|u http://www.degruyter.com/doi/book/10.7312/kahn16298 \|l DE-739 \|p ZDB-23-DGG \|q UPA_PDA_DGG \|x Verlag \|3 Volltext

Datensatz im Suchindex

_version_	1824408274742542336
adam_text
any_adam_object
author	Kahn, Jonathan
author_facet	Kahn, Jonathan
author_role	aut
author_sort	Kahn, Jonathan
author_variant	j k jk
building	Verbundindex
bvnumber	BV042998643
collection	ZDB-23-DGG
ctrlnum	(OCoLC)818814876 (DE-599)GBV739046837
dewey-full	616.042
dewey-hundreds	600 - Technology (Applied sciences)
dewey-ones	616 - Diseases
dewey-raw	616.042
dewey-search	616.042
dewey-sort	3616.042
dewey-tens	610 - Medicine and health
discipline	Medizin
era	Geschichte 2000-2012 gnd
era_facet	Geschichte 2000-2012
format	Electronic eBook
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000zc 4500</leader><controlfield tag="001">BV042998643</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr\|uuu---uuuuu</controlfield><controlfield tag="008">151111s2012 xx o\|\|\|\| 00\|\|\| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780231531276</subfield><subfield code="9">978-0-231-53127-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780231531276</subfield><subfield code="9">978-0-231-53127-6</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.7312/kahn16298</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)818814876</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)818814876</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)GBV739046837</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-859</subfield><subfield code="a">DE-860</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-1046</subfield><subfield code="a">DE-1043</subfield><subfield code="a">DE-858</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.042</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kahn, Jonathan</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Race in a Bottle</subfield><subfield code="b">The Story of BiDil and Racialized Medicine in a Post-Genomic Age</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York</subfield><subfield code="b">Columbia University Press</subfield><subfield code="c">2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (329 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Description based upon print version of record</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">At a ceremony announcing the completion of the first draft of the human genome in 2000, President Bill Clinton declared, ?I believe one of the great truths to emerge from this triumphant expedition inside the human genome is that in genetic terms, all human beings, regardless of race, are more than 99.9 percent the same." Yet despite this declaration of unity, biomedical research has focused increasingly on mapping that .1 percent of difference, particularly as it relates to race.This trend is exemplified by the drug BiDil. Approved by the FDA in 2005 as the first drug with a race-specific ind</subfield></datafield><datafield tag="648" ind1=" " ind2="7"><subfield code="a">Geschichte 2000-2012</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Rassentheorie</subfield><subfield code="0">(DE-588)4152838-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Forschung</subfield><subfield code="0">(DE-588)4017894-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Unternehmensinteresse</subfield><subfield code="0">(DE-588)4187042-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakogenetik</subfield><subfield code="0">(DE-588)4271255-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Hydralazin</subfield><subfield code="0">(DE-588)1031904484</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Medizin</subfield><subfield code="0">(DE-588)4038243-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Rassenpolitik</subfield><subfield code="0">(DE-588)4115694-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Hydralazin</subfield><subfield code="0">(DE-588)1031904484</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Pharmakogenetik</subfield><subfield code="0">(DE-588)4271255-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="4"><subfield code="a">Rassenpolitik</subfield><subfield code="0">(DE-588)4115694-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="5"><subfield code="a">Unternehmensinteresse</subfield><subfield code="0">(DE-588)4187042-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="6"><subfield code="a">Geschichte 2000-2012</subfield><subfield code="A">z</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Medizin</subfield><subfield code="0">(DE-588)4038243-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Forschung</subfield><subfield code="0">(DE-588)4017894-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="3"><subfield code="a">Rassentheorie</subfield><subfield code="0">(DE-588)4152838-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="4"><subfield code="a">Geschichte 2000-2012</subfield><subfield code="A">z</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.degruyter.com/doi/book/10.7312/kahn16298</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-23-DGG</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028423911</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.degruyter.com/doi/book/10.7312/kahn16298</subfield><subfield code="l">DE-1043</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.degruyter.com/doi/book/10.7312/kahn16298</subfield><subfield code="l">DE-1046</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FAW_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.degruyter.com/doi/book/10.7312/kahn16298</subfield><subfield code="l">DE-858</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FCO_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.degruyter.com/doi/book/10.7312/kahn16298</subfield><subfield code="l">DE-859</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FKE_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.degruyter.com/doi/book/10.7312/kahn16298</subfield><subfield code="l">DE-860</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">FLA_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.degruyter.com/doi/book/10.7312/kahn16298</subfield><subfield code="l">DE-473</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">UBG_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.degruyter.com/doi/book/10.7312/kahn16298</subfield><subfield code="l">DE-739</subfield><subfield code="p">ZDB-23-DGG</subfield><subfield code="q">UPA_PDA_DGG</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection>
geographic	USA (DE-588)4078704-7 gnd
geographic_facet	USA
id	DE-604.BV042998643
illustrated	Not Illustrated
indexdate	2025-02-18T15:08:34Z
institution	BVB
isbn	9780231531276
language	English
oai_aleph_id	oai:aleph.bib-bvb.de:BVB01-028423911
oclc_num	818814876
open_access_boolean
owner	DE-859 DE-860 DE-473 DE-BY-UBG DE-739 DE-1046 DE-1043 DE-858
owner_facet	DE-859 DE-860 DE-473 DE-BY-UBG DE-739 DE-1046 DE-1043 DE-858
physical	1 Online-Ressource (329 p)
psigel	ZDB-23-DGG ZDB-23-DGG FAW_PDA_DGG ZDB-23-DGG FCO_PDA_DGG ZDB-23-DGG FKE_PDA_DGG ZDB-23-DGG FLA_PDA_DGG ZDB-23-DGG UBG_PDA_DGG ZDB-23-DGG UPA_PDA_DGG
publishDate	2012
publishDateSearch	2012
publishDateSort	2012
publisher	Columbia University Press
record_format	marc
spelling	Kahn, Jonathan Verfasser aut Race in a Bottle The Story of BiDil and Racialized Medicine in a Post-Genomic Age New York Columbia University Press 2012 1 Online-Ressource (329 p) txt rdacontent c rdamedia cr rdacarrier Description based upon print version of record At a ceremony announcing the completion of the first draft of the human genome in 2000, President Bill Clinton declared, ?I believe one of the great truths to emerge from this triumphant expedition inside the human genome is that in genetic terms, all human beings, regardless of race, are more than 99.9 percent the same." Yet despite this declaration of unity, biomedical research has focused increasingly on mapping that .1 percent of difference, particularly as it relates to race.This trend is exemplified by the drug BiDil. Approved by the FDA in 2005 as the first drug with a race-specific ind Geschichte 2000-2012 gnd rswk-swf Rassentheorie (DE-588)4152838-4 gnd rswk-swf Arzneimittelentwicklung (DE-588)4143176-5 gnd rswk-swf Forschung (DE-588)4017894-8 gnd rswk-swf Unternehmensinteresse (DE-588)4187042-6 gnd rswk-swf Pharmakogenetik (DE-588)4271255-5 gnd rswk-swf Hydralazin (DE-588)1031904484 gnd rswk-swf Medizin (DE-588)4038243-6 gnd rswk-swf Rassenpolitik (DE-588)4115694-8 gnd rswk-swf USA (DE-588)4078704-7 gnd rswk-swf USA (DE-588)4078704-7 g Hydralazin (DE-588)1031904484 s Arzneimittelentwicklung (DE-588)4143176-5 s Pharmakogenetik (DE-588)4271255-5 s Rassenpolitik (DE-588)4115694-8 s Unternehmensinteresse (DE-588)4187042-6 s Geschichte 2000-2012 z 1\p DE-604 Medizin (DE-588)4038243-6 s Forschung (DE-588)4017894-8 s Rassentheorie (DE-588)4152838-4 s 2\p DE-604 http://www.degruyter.com/doi/book/10.7312/kahn16298 Verlag Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk
spellingShingle	Kahn, Jonathan Race in a Bottle The Story of BiDil and Racialized Medicine in a Post-Genomic Age Rassentheorie (DE-588)4152838-4 gnd Arzneimittelentwicklung (DE-588)4143176-5 gnd Forschung (DE-588)4017894-8 gnd Unternehmensinteresse (DE-588)4187042-6 gnd Pharmakogenetik (DE-588)4271255-5 gnd Hydralazin (DE-588)1031904484 gnd Medizin (DE-588)4038243-6 gnd Rassenpolitik (DE-588)4115694-8 gnd
subject_GND	(DE-588)4152838-4 (DE-588)4143176-5 (DE-588)4017894-8 (DE-588)4187042-6 (DE-588)4271255-5 (DE-588)1031904484 (DE-588)4038243-6 (DE-588)4115694-8 (DE-588)4078704-7
title	Race in a Bottle The Story of BiDil and Racialized Medicine in a Post-Genomic Age
title_auth	Race in a Bottle The Story of BiDil and Racialized Medicine in a Post-Genomic Age
title_exact_search	Race in a Bottle The Story of BiDil and Racialized Medicine in a Post-Genomic Age
title_full	Race in a Bottle The Story of BiDil and Racialized Medicine in a Post-Genomic Age
title_fullStr	Race in a Bottle The Story of BiDil and Racialized Medicine in a Post-Genomic Age
title_full_unstemmed	Race in a Bottle The Story of BiDil and Racialized Medicine in a Post-Genomic Age
title_short	Race in a Bottle
title_sort	race in a bottle the story of bidil and racialized medicine in a post genomic age
title_sub	The Story of BiDil and Racialized Medicine in a Post-Genomic Age
topic	Rassentheorie (DE-588)4152838-4 gnd Arzneimittelentwicklung (DE-588)4143176-5 gnd Forschung (DE-588)4017894-8 gnd Unternehmensinteresse (DE-588)4187042-6 gnd Pharmakogenetik (DE-588)4271255-5 gnd Hydralazin (DE-588)1031904484 gnd Medizin (DE-588)4038243-6 gnd Rassenpolitik (DE-588)4115694-8 gnd
topic_facet	Rassentheorie Arzneimittelentwicklung Forschung Unternehmensinteresse Pharmakogenetik Hydralazin Medizin Rassenpolitik USA
url	http://www.degruyter.com/doi/book/10.7312/kahn16298
work_keys_str_mv	AT kahnjonathan raceinabottlethestoryofbidilandracializedmedicineinapostgenomicage

Verfügbarkeit

MARC

Datensatz im Suchindex

‌